{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:08:59Z","timestamp":1775714939974,"version":"3.50.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1097\/fpc.0000000000000231","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T13:54:50Z","timestamp":1464875690000},"page":"397-401","source":"Crossref","is-referenced-by-count":50,"title":["CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals"],"prefix":"10.1097","volume":"26","author":[{"given":"Yasmin","family":"Schmid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Vizeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric M.","family":"Hysek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Prestin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henriette E.","family":"Meyer zu Schwabedissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2012.00235","article-title":"MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relvant?","volume":"3","author":"De la Torre","year":"2012","journal-title":"Front Genet"},{"key":"R2-5-20210213","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/10408444.2012.725029","article-title":"Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug\u2013drug interactions","volume":"42","author":"Rietjens","year":"2012","journal-title":"Crit Rev Toxicol"},{"key":"R3-5-20210213","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants","volume":"93","author":"Hicks","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R4-5-20210213","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0269881106065907","article-title":"Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA","volume":"20","author":"Yang","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R5-5-20210213","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/JCP.0b013e318184ff6e","article-title":"The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans","volume":"28","author":"O\u2019Math\u00fana","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R6-5-20210213","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/clpt.2011.78","article-title":"The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u2018ecstasy\u2019) in humans","volume":"90","author":"Hysek","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R7-5-20210213","doi-asserted-by":"crossref","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","article-title":"Duloxetine inhibits effects of MDMA (\u2018ecstasy\u2019) in vitro and in humans in a randomized placebo-controlled laboratory study","volume":"7","author":"Hysek","year":"2012","journal-title":"PloS One"},{"key":"R8-5-20210213","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1124\/dmd.110.032359","article-title":"Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity","volume":"38","author":"Antolino-Lobo","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R9-5-20210213","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00228-005-0965-y","article-title":"MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers","volume":"61","author":"De la Torre","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R10-5-20210213","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1124\/dmd.108.021543","article-title":"The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers","volume":"36","author":"Meyer","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R11-5-20210213","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2125.2002.01574.x","article-title":"CYP2D6 deficiency, a factor in ecstasy related deaths?","volume":"54","author":"Gilhooly","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R12-5-20210213","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2133\/dmpk.DMPK-12-RG-032","article-title":"Changes in CYP1A2 activity in humans after 3,4-methylene-dioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug","volume":"27","author":"Yubero-Lahoz","year":"2012","journal-title":"Drug Metab Pharmacokinet"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:23:26Z","timestamp":1620951806000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201608000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000231","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}